Human topoisomerase IIalpha: targeting to subchromosomal sites of activity during interphase and mitosis.
D000951:Antigens, Neoplasm; D001324:Autoantigens / Q000032:analysis; D001973:Bromodeoxyuridine / Q000032:analysis / Q000494:pharmacology; D020134:Catalytic Domain; D002467:Cell Nucleus / Q000648:ultrastructure; D000076247:Centromere Protein A; D018385:Centrosome / Q000648:ultrastructure; D002868:Chromosomal Proteins, Non-Histone / Q000032:analysis; D004261:DNA Replication / Q000187:drug effects / Q000502:physiology; D004250:DNA Topoisomerases, Type II / Q000032:analysis* / Q000378:metabolism / Q000502:physiology; D004268:DNA-Binding Proteins; D005047:Etoposide / Q000494:pharmacology; D006367:HeLa Cells; D006570:Heterochromatin / Q000201:enzymology* / Q000648:ultrastructure; D006655:Histone Deacetylases / Q000187:drug effects; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007399:Interphase / Q000502:physiology*; D042581:Intranuclear Space / Q000648:ultrastructure; D018613:Microscopy, Confocal / Q000379:methods; D008856:Microscopy, Fluorescence; D008938:Mitosis / Q000502:physiology*; D012319:RNA Polymerase II / Q000032:analysis; D011929:Razoxane / Q000494:pharmacology
D000951:Antigens, Neoplasm; D001324:Autoantigens; D000076247:Centromere Protein A; D002868:Chromosomal Proteins, Non-Histone; D004268:DNA-Binding Proteins; D006570:Heterochromatin; D006877:Hydroxamic Acids; C060905:centromere protein C; C012589:trichostatin A; D011929:Razoxane; D005047:Etoposide; D012319:RNA Polymerase II; D006655:Histone Deacetylases; D004250:DNA Topoisomerases, Type II; D001973:Bromodeoxyuridine